文献速递头颈与中枢神经肿瘤

腮腺癌保留耳蜗调强放疗与常规放疗随机对照试验(COSTAR)结果

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).
PubMed 文献 · Eur J Cancer · 2018-10-01

COSTAR III期试验将110例腮腺癌术后患者随机分入3DCRT组(54例)或保留耳蜗IMRT组(56例),评估12个月时同侧耳蜗≥10 dB感觉神经性听力损失比例。CS-IMRT显著降低耳蜗剂量(中位35.7Gy vs 56.2Gy,p<0.0001),但12个月听力损失比例无显著差异(36% vs 39%,p=0.81)。

要点

  • CS-IMRT显著降低同侧耳蜗中位剂量至35.7Gy,低于3DCRT的56.2Gy。
  • 12个月时两组≥10 dB听力损失比例无显著差异(36% vs 39%,p=0.81)。
  • 6个月和24个月听力损失及其他次要终点亦无显著差异。

核心结论

  • CS-IMRT降低了耳蜗辐射剂量至耐受量以下,但未减少临床相关听力损失的患者比例。

研究设计与样本

  • III期多中心随机对照试验(COSTAR;CRUK/08/004),2008年8月至2013年2月从22个英国中心入组110例pT1-4 N0-3 M0腮腺癌患者。
  • 患者1:1随机分配至3DCRT组(54例)或CS-IMRT组(56例),按中心和60Gy或65Gy/30次剂量分层。
  • 主要终点为放疗后12个月同侧耳蜗4000Hz骨传导≥10 dB感觉神经性听力损失比例,采用Fisher精确检验比较。

主要发现

  • 同侧耳蜗中位剂量:3DCRT组56.2Gy,CS-IMRT组35.7Gy(p<0.0001)。
  • 110例中67例(61%)可评估主要终点,不可评估主要原因为未随访或听力评估不完整。
  • 12个月时3DCRT组14/36(39%)和CS-IMRT组11/31(36%)出现≥10 dB听力损失(p=0.81)。
  • 6个月和24个月听力损失及其他次要终点(包括患者报告的听力结局)均无统计学显著差异。

临床怎么用

  • CS-IMRT可显著降低耳蜗剂量,但本研究未证明其能减少临床相关听力损失,选择技术时需综合考虑其他因素。

局限性

  • 仅61%患者可评估主要终点,主要因未随访或听力评估不完整,可能影响统计效力。
  • 研究未报告样本量计算依据及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III trial, investigated the role of cochlear-sparing IMRT (CS-IMRT) in reducing hearing loss. METHODS: Patients (pT1-4 N0-3 M0) were randomly assigned (1:1) to 3-dimensional conformal radiotherapy (3DCRT) or CS-IMRT by minimisation, balancing for centre and radiation dose of 60Gy or 65Gy in 30 daily fractions. The primary end-point was proportion of patients with sensorineural hearing loss in the ipsilateral cochlea of ≥10 dB bone conduction at 4000 Hz 12 months after radiotherapy compared using Fisher's exact test. Secondary end-points included hearing loss at 6 and 24 months, balance assessment, acute and late toxicity, patient-reported quality of life, time to recurrence and survival. RESULTS: From Aug 2008 to Feb 2013, 110 patients (54 3DCRT; 56 CS-IMRT) were enrolled from 22 UK centres. Median doses to the ipsilateral cochlea were 3DCRT: 56.2Gy and CS-IMRT: 35.7Gy (p < 0.0001). 67/110 (61%) patients were evaluable for the primary end-point; main reasons for non-evaluability were non-attendance at follow-up or incomplete audiology assessment. At 12 months, 14/36 (39%) 3DCRT and 11/31 (36%) CS-IMRT patients had ≥10 dB loss (p = 0.81). No statistically significant differences were observed in hearing loss at 6 or 24 months or in other secondary end-points including patient-reported hearing outcomes. CONCLUSION: CS-IMRT reduced the radiation dose below the accepted tolerance of the cochlea, but this did not lead to a reduction in the proportion of patients with clinically relevant hearing loss.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nutting CM, Morden JP, Beasley M, et al. Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). Eur J Cancer. 2018. PMID: 30286418. doi:10.1016/j.ejca.2018.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。